Phonatory function and characteristics of voice in recovering COVID-19 survivors

Dalia G. Yasien1 · Eman S. Hassan2 · Hanan A. Mohamed2

Received: 2 February 2022 / Accepted: 21 April 2022 / Published online: 15 May 2022
© The Author(s) 2022

Abstract
Introduction This study aimed to evaluate the phonatory function of recovered COVID-19 survivors. The universal outbreak of COVID-19 led to the occurrence of otolaryngological manifestations that raised concerns about the assessment of the phonatory function in recovering patients.

Methods This is a prospective, cross-sectional, case-controlled study carried out on 364 laboratory-confirmed non-critical COVID-19 survivors and 100 as healthy controls. The study participants were classified into two groups according to the disease severity. Group 1 comprised 212 survivors who recovered from pneumonia and group 2 was made up of 152 survivors of severe pneumonia. All patients were subjected to an auditory perceptual assessment of the voice (APA) and Maximum Phonation Time (MPT) measurements.

Results Phonasthenic manifestations were significantly more frequent in COVID-19 survivors than in controls (P < 0.000) with a higher percentage recorded among severe pneumonia survivors (87.5%) than among pneumonia survivors (60.8%) with a P value of < 0.01. Dysphonia and excessively soft loudness were significantly more common among survivors than among controls (P < 0.002 and P < 0.000, respectively) with no significant difference between the patient groups. The MPT was significantly shorter among survivors than among controls (P<0.000). The mean MPT was 15.97 s in the control group, 10.72 s in the pneumonia group, and 8.88 s in the severe pneumonia group, with the differences between the groups being statistically significant (P<0.000), suggesting a higher impairment of lung volume and phonatory function in severe cases.

Conclusions Phonasthenia, dysphonia, and decreased MPT could be otolaryngological manifestations of COVID-19. Laryngeal function assessment should be considered in COVID-19 survivors.

Keywords Phonasthenia · Dysphonia · COVID-19 survivors · MPT · Pneumonia

Introduction

Coronavirus disease 2019 (COVID-19) is a contagious illness caused by a novel coronavirus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, formerly called 2019-nCoV) [1]. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic [2].

In the light of commonly documented lung injuries related to COVID-19 [3, 4], concerns are raised about the evaluation of the pulmonary function of discharged patients. Persistent impairments of the pulmonary function and exercise capacity have been known to last for months or even years in recovered survivors of other types of coronavirus pneumonia [5–7]. Voice production depends on a finely balanced relationship between the forces exerted by the intrinsic muscles of the larynx and the forces exerted by the air as it is exhaled from the lung. This occurs through what is called the aerodynamic-myoelectric theory of phonation, which states that the vibration of the vocal folds is induced by a combination of the aerodynamic, muscular, and elastic forces of the larynx [8].

An abnormal pulmonary function and a reduced pulmonary vital capacity affect voice quality and the maximum phonation time (MPT) [9]. Colton and Casper (1990)
suggested that the ability to sustain phonation provides information about the laryngeal function and the pulmonary function at the same time. When the pulmonary function is the problem, there will be a reduction in the amount of air needed to support phonation. On the other hand, in the case of laryngeal-level problems, glottal resistance to airflow may increase or decrease due to hyper-adduction or the inadequate closing of the glottis [10]. A recent report presented pulmonary function abnormalities in COVID-19 patients at the time of hospital discharge [11]. However, to the best of our knowledge, there is no available report on the laryngeal function in recovered COVID-19 patients.

Many parameters can be used in describing the laryngeal function. These include the assessment of voice quality, acoustic measurements, and aerodynamic measurements. The MPT is an easy aerodynamic measure as it is rapid, non-invasive, and requires no special equipment.

In this study, we aimed to evaluate the phonatory function of recovered COVID-19 survivors by assessing the voice quality and MPT.

Patients and methods

Patients

Three hundred sixty-four laboratory-confirmed non-critical COVID-19 survivors and 100 healthy controls were recruited in this prospective cross-section case-control study that was carried out from July 2020 to April 2021. According to the WHO interim guidance [12], the disease was classified as mild illness (mild symptoms without any radiographic appearance of pneumonia), pneumonia (the presence of both symptoms and radiographic evidence of pneumonia with no requirement for supplemental oxygen), severe pneumonia (the presence of pneumonia with at least one of the following: respiratory rate > 30 cycles/minute, severe respiratory distress, or SpO2 ≤ 93% on room air at rest), and critical cases (e.g., respiratory failure requiring mechanical ventilation, septic shock, other organ failures, or admission to the intensive care unit). Two hundred and twelve survivors who recovered from pneumonia (Group 1) and 152 survivors from severe pneumonia (Group 2) were enrolled in this study while mild and critical cases were excluded. We also excluded people with a previous history of voice disorders, asthma, or any form of respiratory disease.

Methods

Every patient’s full history was taken during an interview. The auditory perceptual assessment of the voice (APA) was evaluated by three phoniatricians after recording the participant’s speech. Speech samples included reading a standardized text or counting and isolated vowel phonation at a comfortable pitch and loudness as naturally as possible. The voice sample was obtained by recording the patient’s voice with an audio recorder in a quiet environment. The patients were asked to phonate a prolonged /a/ vowel sound with normal intensity and pitch. In addition, they were asked to count from one to ten.

Auditory perceptual assessments of voice samples were performed using the protocol of the modified GRBAS scale [13] that evaluates:

- The overall grade (G) of dysphonia: Normal (0), Mild dysphonia (1), Moderate dysphonia (2), or severe dysphonia (3).
- The character (quality) of dysphonia: Strained, Leaky, Breathy, or Irregular.
- The pitch: Overall increased, Decreased, or Diplophonia.
- The register: Modal, Falsetto, or Fry.
- The loudness: Excessively loud, Excessively soft, or Fluctuating.
- The glottal attack: Normal, Soft, or Hard.

Cronbach’s alpha test was used to measure the scale reliability. The overall grading of dysphonia of the three examiners revealed high inter-rater reliability (Cronbach’s Alpha = 0.89).

The MPT was calculated using an audio recorder and stopwatch. This parameter was measured by asking each patient while sitting upright, to take a deep breath and then to sustain the /a:/ vowel sound for as long as possible at his/her comfortable pitch and loudness without straining. The task was repeated three times and the longest duration of the three attempts is considered as the MPT.

Ethical considerations

The study was approved by the research ethics committee of the Faculty of Medicine-Helwan University. All participants gave their written informed consent to participate in the study.

Statistics

The data were entered into Statistical Package for the Social Sciences version 24 and the same software program was used for data analyses. Quantitative variables were presented as mean values with standard deviations for normally distributed data and as median values with interquartile ranges for variables with skewed data distributions. Categorical data were presented as frequencies and percentages. The chi-square test was used to compare between categorical variables while the independent sample t test and the ANOVA test were used to compare quantitative variables between
groups. \( P \) values of less than 0.05 were considered statistically significant.

### Results

The demographic data of the participants in the different study groups are presented in Table 1. No significant differences in age, sex, smoking status, and height were observed between the three groups. Phonasthenic manifestations (Table 2) were present in 60.8\% of patients with pneumonia, 87.5\% of patients with severe pneumonia, and 12\% of the control participants with a highly significant difference between the three groups. Table 3 shows highly significant differences in voice quality, register, and loudness between COVID-19 survivors and control participants with no significant difference between the pneumonia and severe pneumonia groups. There was no significant difference in the pitch and glottal attack between the discharged COVID-19 survivors of both groups and the control participants (Table 4). Table 5 shows a highly significant difference in the MPT between the groups; 15.97 ± 3.91 s in the control group, 10.72 ± 4.09 in the pneumonia group, and 8.88 ± 2.68 in the severe pneumonia group.

### Discussion

The universal outbreak of COVID-19 led to the occurrence of otolaryngological manifestations of this infection, which are mainly related to the loss of smell and taste. However, many other otolaryngological symptoms could be predominant in COVID-19, raising concerns about the assessment of the laryngeal function in recovering patients. There is currently no report on the laryngeal function in discharged COVID-19 survivors. This study aimed to assess the laryngeal function by evaluation of voice quality and MPT of recovered COVID-19 survivors. Phonasthenia is a functional voice disorder in which dysphonia is not heard but felt in the neck and throat by the patients [14]. In this study, 262 (72\%) COVID-19 survivors had phonasthenic manifestations in the form of dryness of the throat, easy fatigability of the voice, frequent throat clearance, and throat soreness. We also reported that phonasthenic manifestations had a direct relationship with the severity of illness as they were significantly

### Table 1

| Item                | Group 1 “Pneumonia” \( n=212 \) | Group 2 “Severe Pneumonia” \( n=152 \) | Group 3 “Control” \( n=100 \) | \( P \) value |
|---------------------|---------------------------------|---------------------------------|-------------------------------|--------------|
| Sex                 |                                 |                                 |                               | P=0.977      |
| Male                | 103 (48.6\%)                   | 75 (49.3\%)                    | 48 (48.0\%)                   |              |
| Female              | 109 (51.4\%)                   | 77 (50.7\%)                    | 52 (52.0\%)                   |              |
| Smoking             |                                 |                                 |                               | P=0.640      |
| Yes                 | 91 (42.9\%)                    | 69 (45.4\%)                    | 43 (43.0\%)                   |              |
| No                  | 121 (57.1\%)                   | 83 (54.6\%)                    | 57 (57.0\%)                   |              |
| Age                 |                                 |                                 |                               | P=0.291      |
| Mean ± SD Range     | 53.71 ± 13.77 (23.0–76.0)      | 52.4 ± 12.23 (24.0–76.0)       | 51.15 ± 15.82 (22.0–75.0)    |              |
| Height              |                                 |                                 |                               | P=0.369      |
| Mean ± SD Range     | 168.15 ± 12.42 (148.0–185.0)   | 166.12 ± 16.27 (150.0–187.0)   | 167.31 ± 14.17 (150.0–185.0) |              |

Sex & smoking \( P \) value using Chi-square test, Age & Height \( P \) value using ANOVA test

### Table 2

| Item                | Group 1 “Pneumonia” \( n=212 \) | Group 2 “Severe Pneumonia” \( n=152 \) | Group 3 “Control” \( n=100 \) | \( P \) value |
|---------------------|---------------------------------|---------------------------------|-------------------------------|--------------|
| Phonasthenic manifestations |                                 |                                 |                               | P<0.000      |
| Yes                 | 129 (60.8\%)                   | 133 (87.5\%)                   | 12 (12.0\%)                   | P<0.000      |
| No                  | 83 (39.2\%)                    | 19 (12.5\%)                    | 88 (88.0\%)                   | **P<0.000    |

Using Chi-Square test \( *P \); group 1 to group 3, \( **P \); group 2 to group 3 \( ***P \); group 1 to group 2
### Table 3
Auditory perceptual assessment of the voice: voice quality, register, and loudness in the different groups

| Item | Group 1 “Pneumonia” “n = 212” | Group 2 “Severe Pneumonia” “n = 152” | Group 3 “Control” “n = 100” | P value |
|------|--------------------------------|--------------------------------------|----------------------------|---------|
| Grade of dysphonia | | | | |
| 0 | 179 (84.4%) | 125 (82.2%) | 100 (100.0%) | P < 0.002 |
| 1 | 26 (12.3%) | 19 (12.5%) | 0 | *P < 0.01 |
| 2 | 4 (1.9%) | 6 (3.9%) | 0 | **P < 0.01 |
| 3 | 3 (1.4%) | 2 (1.3%) | 0 | ***P = 0.699 |
| Total number of patients with dysphonia | 33 (15.6%) | 27 (17.7%) | 0 | |
| Voice quality | | | | |
| Normal | 179 (84.4%) | 125 (82.2%) | 100 (100.0%) | P < 0.000 |
| Leaky | 13 (6.1%) | 18 (11.8%) | 0 | *P < 0.001 |
| Rough | 9 (4.2%) | 2 (1.3%) | 0 | **P < 0.001 |
| Strained & Leaky | 11 (5.2%) | 7 (4.6%) | 0 | ***P = 0.435 |
| Register | | | | |
| Modal | 139 (65.6%) | 97 (63.8%) | 91 (91.0%) | P < 0.000 |
| Modal with vocal fry | 73 (34.4%) | 55 (36.2%) | 9 (9.0%) | *P < 0.000 |
| | | | **P < 0.000 |
| | | | ***P = 0.661 |
| Loudness | | | | |
| Normal | 149 (70.0%) | 101 (66.4%) | 91 (91.0%) | P < 0.000 |
| Excessively soft | 62 (29.2%) | 51 (33.6%) | 7 (7.0%) | *P < 0.000 |
| Excessively loud | 1 (0.5%) | 0 | 2 (2.0%) | **P < 0.000 |
| | | | ***P = 0.488 |

Using Chi-Square test, *P; group 1 to group 3, **p; group 2 to group 3, ***P; group 1 to group 2

### Table 4
Comparison of the auditory perceptual assessment of the voice, “pitch & glottal attack,” between the three groups

| Item | Group 1 “Pneumonia” “n = 212” | Group 2 “Severe Pneumonia” “n = 152” | Group 3 “Control” “n = 100” | P-value |
|------|--------------------------------|--------------------------------------|----------------------------|---------|
| Pitch | | | | |
| Normal | 212 (100%) | 152 (100%) | 100 (100%) | – |
| Glottal attack | | | | |
| Normal | 205 (96.7%) | 148 (97.4%) | 100 (100%) | P = 0.402 |
| Soft | 6 (2.8%) | 4 (2.6%) | 0 | *P = 0.185 |
| Hard | 1 (0.5%) | 0 | 0 | **P = 0.102 |
| | | | ***P = 0.693 |

Using Chi-Square test *P; group 1 to group 3, **p; group 2 to group 3 ***P; group 1 to group 2

### Table 5
Comparison of the maximum phonation time between the three groups

| Item | Group 1 “Pneumonia” “n = 212” | Group 2 “Severe Pneumonia” “n = 152” | Group 3 “Control” “n = 100” | P value |
|------|--------------------------------|--------------------------------------|----------------------------|---------|
| MPT in seconds | 10.72 ± 4.09 | 8.88 ± 2.68 | 15.97 ± 3.91 | P < 0.000 |
| (mean ± SD) | (4.55–22.3) | (4.74–16.22) | (6.00–22.06) | *P < 0.000 |
| Range | | | **P < 0.000 |
| **P < 0.000 | |
| MPT in Males | 11.72 ± 4.53 | 10.42 ± 2.64 | 17.89 ± 4.23 | P < 0.000 |
| MPT in Females | 9.75 ± 3.36 | 7.37 ± 1.67 | 14.05 ± 2.79 | P < 0.000 |

Using ANOVA test & independent T test *P; group 1 to group 3, **p; group 2 to group 3 ***P; group 1 to group 2
more frequent in patients with severe pneumonia than in those with pneumonia. The most common predisposing factors to phonasthenia were the misuse and abuse of the voice, smoking, poor physical condition, and generalized fatigue [14, 15]. Generalized fatigue and poor physical condition are common in patients with confirmed COVID-19 [16, 17], that is associated etiologically with phonasthenia [15]. Carfi et al. 2020 found that 53% of COVID-19 survivors experienced fatigue and 43% of them reported dyspnea and shortness of breath [18]. The association between chronic fatigue and voice complaints has been reported in a previous study on young singers [19]. Dysphonia is a change in the vocal quality, pitch, loudness, or vocal exertion that impairs communication. It affects one-third of people at a certain point in their lives and is encountered in less than 20% of common viral infections such as a common cold or flu [20, 21]. In the present study, varying degrees of dysphonia, from mild to severe, with abnormal qualities of the voice (leaky, strained, and rough) were recorded in 15.6% of COVID-19 survivors with pneumonia and 17.7% of COVID-19 survivors while aphonia was reported in 3.7% of patients [22].

Our findings are in line with those of Jerome et al. who reported that the prevalence of dysphonia in COVID-19 remains lower than that of other common symptoms such as the total loss of smell and taste [20]. Vocal fry register was observed in 34.4% of COVID-19 with pneumonia and in 36.2% of COVID-19 with severe pneumonia. Moreover, excessively soft phonation was observed in 29.2% and 33.6% of patients who had COVID-19 with pneumonia and severe pneumonia, respectively. These findings could be explained by the generalized weakness, fatigue, and shortness of breath that affected their voices and rendered them weak (perceptually). However, there was no significant difference in these auditory perceptual characteristics between the pneumonia and severe pneumonia groups. Phonasthenic manifestations and altered auditory perceptual characteristics could be likely related to the laryngeal involvement in the airway inflammatory process and may be caused by cough-related injuries [23]. Coughing slams the vocal folds forcefully together to clear mucus, and cough-related injuries to the vocal folds’ mucosa may affect the vibration of these structures to varying degrees of severity [24]. It is known that respiratory weakness can modify the vocal patterns, influencing the maintainability of vocal production [25] and the efficient use of the breath is essential for healthy phonation [24]. Recent studies have revealed that the lung is the organ that is most affected by COVID-19 [2, 3] which results in an impairment of the phonatory function. Our results show a worsening of the MPT in COVID-19 survivors compared with the control group. The mean MPT was significantly lower in the severe pneumonia group than in the pneumonia group, which suggests higher impairment of the lung volume and phonatory function in severe cases.

In conclusion, our study revealed that in discharged COVID-19 survivors, phonasthenia is a common complaint and its incidence increased with the severity of the illness and that it should be considered a symptom of the disease. Dysphonia may be encountered in patients with moderate-to-severe disease. Physicians have to keep in mind that COVID-19 patients may develop dysphonia throughout the clinical course of the disease as it usually occurs in common viral infection of the upper aerodigestive tract mucosa. The decrease in the MPT among patients was in line with the varying degree of severity of the disease among the patients.

**Limitations**

The cross-sectional study design did not allow us ample time for follow-up.

The association between phonasthenic manifestations, the abnormal voice quality, the shortened MPT, and the laryngostroboscopic evaluation was not determined in our study to avoid the risk of contamination associated with the video laryngostroboscopic examination.

**Recommendations**

The long-term evaluation of the phonatory function after recovery still requires further investigations that include stroboscopic examinations of the vocal folds. More studies are needed to explore the place of phonasthenia and dysphonia as clinical manifestations of COVID-19, and the etiology of phonatory function impairment in COVID-19 patients requires more investigations.

**Funding** Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). No financial support has been received for this study.

**DECLARATIONS**

**Conflict of interest** None of the authors have any potential conflict of interest to declare.

**Ethical approval** The study was approved by the research ethics committee of the Faculty of Medicine-Helwan University. All participants
gave their written informed consent to participate in the study (43-2020).

Consent to participate Applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55(3):105924
2. WHO (2020)Director-General’s opening remarks at the media briefing on COVID-19 March
3. Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062
4. Xu Z, Shi L, Wang YJ et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422
5. Hui DS, Wong KT, Ko FW et al (2005) The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 128(4):2247–2261
6. Ngai JC, Ko FW, Ng SS et al (2010) The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 15(3):543–550
7. Park WB, Jun KL, Kim G et al (2018) Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome. J Korean Med Sci 33(24):e169
8. Seikel JA, King DW, Drumright DG (2000) Anatomy and Physiology of speech, language and hearing, 2nd edn. Singular publishing group Inc, SanDiego
9. dos Santos KW, Echeveste SS et al (2014) Association between lung function and vocal affections arising from tobacco consumption. Int Arch Otorhinolaryngol 18(1):11–15
10. Colton R, Casper J (1990) Understanding voice problems: a physiological perspective for diagnosis and treatment. Baltimore, Williams & Wilkins
11. Mo X, Jian W, Su Z et al (2020) Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 55(6):2001217
12. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Released by World Health Organization on 13 March 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfectionwhen-novel-coronavirus-(ncov)-infection-is-suspected
13. Kotby MN (1986) Voice disorders; recent diagnostic advances. Egypt J Otolaryngol 3(10):69–98
14. Kotby MN (1995) The accent method of voice therapy. Singular Publishing Group Inc., San Diego, California
15. StatalotFR (1986) The professional voice. In: Cummings C et al (eds) Otolaryngology head and neck surgery. St. Louis Morby, pp 2029–2053
16. Zou S, Liu Z-H, Yan X et al (2020) Prevalence and correlates of fatigue and its association with quality of life among clinically stable older psychiatric patients during the COVID-19 outbreak: a cross-sectional study. Global Health 16(1):119
17. Qi R, Chen W, Liu S, Thompson PM, Zhang LJ, Xia F et al (2020) Psychological morbidity and fatigue in patients with confirmed COVID-19 during disease outbreak: prevalence and associated. medRxiv 7(3):228
18. Carfi A, Bernardi L, Landi F, Against G, COVID-19 Post-Acute Care Study group (2020) Persistent symptoms in patients after acute COVID-19. JAMA 324(6):603–605
19. Tepe ES, Deutsch ES, Sampson Q et al (2002) A pilot survey of vocal health in young singers. J Voice 16:244–250
20. Lechien JR, Chiesa-Estomba CM, Cabaraux P et al (2020) Features of mild-to-moderate COVID-19 patients with dysphonia. J Voice. https://doi.org/10.1016/j.jvoice.2020.05.012
21. Stachler RJ, Francis DO et al (2018) Clinical practice guideline: hoarseness (dysphonia) (update). Otolaryngol Head Neck Surg 158(suppl 1):S1-42
22. Lechien JR, Chiesa-Estomba CM, De Siati DR et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 277(8):2251–2261
23. Sanasiaya J, Kulasegarah J, Narayanan P (2021) New-onset dysphonia: a silent manifestation of COVID-19. Ear, Nose, Throat J. https://doi.org/10.1177/0145561321995008
24. Lynn H, Carroll Thomas L, John N, Johns Michael M, LeBorgne WD, David M (2020) COVID-19 after effects: concerns for singers. J Voice S0892–1997(20):30281–30282
25. Miglioranz SL, Santa M (2010) Universidade Federal de Santa Maria. Capacidade vital etempos máximos de fonação de /e/ áfono e /s/ em mulheres adultas [thesis] [Google Scholar]